|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
Review paper
Prolonged activated partial thromboplastin time in pediatric patients – an important diagnostic challenge
Aleksandra Zima
1, 2
,
Joanna Zdziarska
3
Pediatr Pol 2025; 100 (4)
Online publish date: 2025/11/24
Article file
- Prolonged activated.pdf
[0.19 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Santoro RC, Molinari AC, Leotta M, Martini T. Isolated prolongation of activated partial thromboplastin time: not just bleeding risk! Medicina 2023; 59: 1169. 2.
Sierra C, Moreno M, García-Ruiz JC. The physiology of hemostasis. Blood Coagul Fibrinolysis 2022; 33: S1-S2. 3.
Loizou E, Mayhew D, Martlew V, Murthy BVS. Implications of deranged activated partial thromboplastin time for anaesthesia and surgery. Anaesthesia 2018; 73: 1557-1563. 4.
Chojnowski K, Podolak-Dawidziak M, Windyga J. Diagnosis of the prolonged activated partial thromboplastin time (aPTT). Hematologia 2010; 1: 81-86. 5.
Zdziarska J, Chojnowski K, Klukowska A, Łaguna P, Łętowska M, Mital A, et al. Postępowanie w chorobie von Willebranda. Zalecenia Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów 2022. J Transfus Med 2022; 15: 100-126. 6.
Blanchette VS, Kahr WHA. Work-up of a bleeding child. In: Lee CA, Berntorp EE, Hoots KW (eds.). Textbook of hemophilia. Blackwell Publishing, Oxford 2005, 112-119. 7.
Toulon P, Berruyer M, Brionne-François M, Grand F, Lasne D, Telion C, et al. Age dependency for coagulation parameters in paediatric populations. Results of a multicentre study aimed at defining the age-specific reference ranges. Thromb Haemost 2016; 116: 9-16. 8.
Rasmussen KL, Philips M, Tripodi A, Goetze JP. Unexpected, isolated activated partial thromboplastin time prolongation: a practical mini-review. Eur J Haematol 2020; 104: 519-525. 9.
Liu J, Li F, Shu K, Chen T, Wang X, Xie Y, et al. The analysis of false prolongation of the activated partial thromboplastin time (activator: Silica): interference of C-reactive protein. J Clin Lab Anal 2018; 32: e22571. 10.
Erdem-Eraslan L, Hens JJH, van Rossum AP, Frasa MAM, Keuren JFW. Inter-individual variability in phospholipid-dependent interference of C-reactive protein on activated partial thromboplastin time. Br J Haematol 2018; 183: 681-683. 11.
Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007; 53: 1629-1635. 12.
Betensky M, Mosha M, Tarango C, Verma A, Bhat R, Kucine NE, Nakano T, et al. Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trial. Blood Adv 2024; 8: 5790-5795. 13.
Halbmayer WM, Haushofer A, Schon R, Mannhalter C, Strohmer E, Baumgarten K, et al. The prevalence of moderate and severe FXII (Hageman factor) deficiency among the normal population: evaluation of the incidence of FXII deficiency among 300 healthy blood donors. Thromb Haemost 1994; 71: 68-72. 14.
Schmaier AH. The elusive physiologic role of Factor XII. J Clin Invest 2008; 118: 3006-3009. 15.
Mouthon P, Guy A, d’Oiron R, Harroche A, Lebreton A, Gourguechon C, et al. Acquired haemophilia A in paediatric patients: a retrospective French cohort of eight cases. Br J Haematol 2024; 204: 606-611. 16.
Windyga J, Chojnowski K, Klukowska A, Łaguna P, Łętowska M, Mital A, et al. Emicizumab (Hemlibra®) u chorych na hemofilię A powikłaną inhibitorem czynnika VIII – wytyczne Grupy ds. Hemostazy Polskiego Towarzystwa Hematologów i Transfuzjologów. J Transf Med Hemost 2020; 13: 153-164. 17.
Feriel J, Goujon MA, Desez M, Depasse F. Impact of drugs used in intensive care on routine coagulation testing. Diagnostics (Basel) 2025; 15: 941.
Copyright: © 2025 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
POLSKI
